Laura Berner
Chief Operating OfficerMs. Laura Berner, JD, MBA serves as an Independent Director of Bolt Biotherapeutics, Inc. from December 14, 2022. She serves as Chief Operating Officer of TRex Bio, Inc. since May 2022 and served as its Chief Business Officer from August 2020 until 2022. Ms. Berner has extensive experience in corporate development, corporate and strategic transactions, investor relations, strategy and operations. Most recently, she was Vice President and Head of Business Development & Investor Relations at Myovant Sciences Ltd., from 2018 to 2020 where she led the execution of global partnering transactions for the commercialization of its lead product (relugolix) and supported it through multiple follow-on financings. Earlier in her career, she was a member of the Transactions team with Roche Pharma Partnering, where she was responsible for leading transactions across the fields of oncology, immunology, neuroscience, infectious and rare diseases and the transactional law group at Genentech. She began her career as a corporate attorney first at Ropes & Gray LLP and later in the Office of the General Counsel at Harvard University, advising on general corporate, business development and strategic partnering transactions. Ms. Berner obtained her BA in biology magna cum laude from Bryn Mawr College and her JD from Stanford Law School, where she was an Executive Editor on the Stanford Law Review. She earned MBA from the University of Illinois Urbana Champagne Gies College of Business.
Positions
- Company NameTRex Bio, Inc.Stock CodeTRXBPositionChief Operating OfficerColleagues
